|
|
 |
 |
 |
| |
 |
 |
|
|
|
Market Research to Gain the Competitive Edge |
Customer Loyalty |
Designed to help our clients attract and
retain loyal customers, the High Tech Business Decisions Customer
Loyalty Program includes assessments of customer satisfaction
and loyalty, performance ratings and comparisons to competitors,
and discernment of current customers' future plans. |
|
| |
Industry Insights |
The following directories of leading edge suppliers are provided as a courtesy.
|
|
|
|
|
| |
|
"With expertise
in complex pharmaceutical drug discovery, biomanufacturing,
and electronics manufacturing technologies, our highly trained
analysts investigate markets for high tech business-to-business
products and services. Our custom reports are in-depth analyses
that bring leading edge science together with profitable
business strategies for the pharmaceutical and electronics
industries." William P. Downey, President
New Report Just Published, January
2013
Biopharmaceutical Contract Fill-and-Finish:
Best Practices Study 2013
This 660-page report, the comprehensive 2013 industry study, provides the latest information on fill-and-finish outsource plans, technologies, markets, supply and demand, client-contractor relationships, price policies and practices, prices paid, and future trends in fill-and-finish contract manufacturing industry. This report highlights both the growth opportunities and challenges facing the contract fill-and-finish industry with respect to aseptic fill. The data and the analysis in this report are based on 42 in-depth interviews with biomanufacturing directors at pharmaceutical and biotechnology companies, and executives from fill-and-finish contract manufacturing organizations worldwide. Detailed information is also presented from 56 contract manufacturing organizations. The analysis of these perspectives provides the readers with insights to understand current and future trends in the biopharmaceutical contract fill-and-finish market. This report includes over 200 summary data tables and charts, and is the most comprehensive and current industry report on biopharmaceutical fill-and-finish contract manufacturing. Published January 2013
Directory of Biopharmaceutical
Fill-and-Finish Contract Manufacturers
The 2013 directory provides a thorough listing
of 56 biopharmaceutical fill-and-finish contractors worldwide,
including information on type of services offered, equipment
capacity, cGMP certification by service category and more
High Throughput Screening 2012: Improved Strategies, Adaptive Technologies and Enhanced Assays
This 850-page report, with over 270 charts and tables, documents the current and future role of HTS in drug discovery activities. The data and analysis contained in this report comes from extensive discussions with both HTS laboratory directors and HTS industry suppliers who were interviewed by our Ph.D.-level analysts. This report provides in-depth analysis of current HTS laboratory practices and budgets at drug innovator companies, academic and government research centers, and contract research organizations. This report documents the current and future use of high content screening, detection technologies, automation equipment, reagents, cell lines, and various targets and target classes. In addition, this report details the number of compounds screened, the level of screening activity, the use of various microplate formats, and the unmet needs of the HTS laboratory directors. Also in included in this report is a comprehensive examination of current and future spending by major product categories and by HTS laboratory segments. Published July 2012
Biopharmaceutical Contract Manufacturing
2011:
New Participants, Expanded Services and Emerging Markets
This 900-page report provides the latest information about the supply and demand for the outsource production of large-molecule API. This report analyzes the biotechnology industry's biomanufacturing strategies, budgets, contractor relationships and new projects. This report also provides detailed analyses of contractor capacity, current and projected utilization rates, and the adoption of disruptive manufacturing technologies. The data and the analysis in this report are based on 70 in-depth interviews conducted by Ph.D.-level analysts with both executives at biopharmaceutical and contractor companies worldwide. The analyses of their perspectives and insights allow readers to gain an understanding of the market and its future direction. This report includes 235 summary data tables and charts, and is the most comprehensive and current industry report on biopharmaceutical contract manufacturing. Published October 2011.
Directory of Biopharmaceutical Contract Manufacturers
The 2011 directory provides a thorough listing of 77 contractors worldwide, including service offerings, equipment, capacity, cGMP status, and other important details
Biopharmaceutical Contract Manufacturing:
Best Practices Pricing Study 2011
This 300-page report documents pricing practices,
policies, agreements, and strategies for both pharmaceutical
and biotechnology companies and contract manufacturers. Learn
about industry prices paid to contractors for mammalian cell
culture and microbial fermentation production. This report provides
batch, time-in-facility, and gram prices. In this report, contract
manufacturing prices are analyzed by technology and tank sizes.
This report includes both prices paid by users and prices charged
by CMOs for contract services. In addition, this report provides
extensive information from industry executives on difficult-to-negotiate
issues such as liability for failed batches, down payments,
cancellation fees, technology transfer fees, process development
fees, and more. Published January 2011.
The History
of High Throughput Screening for Drug Discovery:
1998-2005
HighTech Business
Decisions (HTBD) has conducted six market research studies
and published six comprehensive industry reports on high throughput
screening (HTS) since 1998. This report is specifically designed
to understand the changes that have occurred in HTS since
1998, how accurate HTS directors have been in forecasting
and predicting their use of technology and future needs, how
HTS practices have evolved, and the success of HTS as a drug
discovery tool. Topics include the number of disease targets
screened, target types, assay types, detection modes, microplate
formats, outsourcing, and other issues impacting HTS operations
and success. The complete analysis, based on both user and
supplier primary research, includes market size and growth,
major players, user strategies and requirements, documentation
of success in drug discovery, trends and technologies, and
respondents’ perceptions regarding the future of HTS.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| info@HighTechDecisions.com
|
|
|
|
|
|
|
|
|
|
|